- Conditions
- Hypertension
- Interventions
- Aliskiren, Enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 9,360
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Larotrectinib (Vitrakvi, BAY2757556)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more
- Conditions
- Anemia
- Interventions
- methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
- Conditions
- Metastatic Carcinoma, Metastatic Sarcoma, Metastatic Lymphoma
- Interventions
- 2.4 mg/kg α-TEA, 4.8 mg/kg α-TEA, 8.0 mg/kg α-TEA, 9.6 mg/kg α-TEA, 12 mg/kg α-TEA, 16.8 mg/kg α-TEA, 19.2 mg/kg α-TEA, 22.3 mg/kg α-TEA, 26.8 mg/kg α-TEA
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Clackamas, Oregon • Newberg, Oregon • Oregon City, Oregon + 1 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
- Conditions
- Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
- Interventions
- 2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 60
- States / cities
- Campbell, California • Glendale, California • Huntington Beach, California + 50 more
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Disturbed Sleep
- Interventions
- Ashwagandha, Placebo
- Dietary Supplement · Other
- Lead sponsor
- National University of Natural Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
- Conditions
- Alzheimer's Disease
- Interventions
- Crenezumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 32
- States / cities
- Newport Beach, California • Redlands, California • Sacramento, California + 28 more
- Conditions
- Traumatic Brain Injury
- Interventions
- FM system, Auditory training
- Device · Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Portland, Oregon
- Conditions
- Ulcerative Colitis
- Interventions
- mesalamine
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 19 more
- Conditions
- ADHD
- Interventions
- Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 100 mg
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 33
- States / cities
- Los Angeles, California • National City, California • Newport Beach, California + 27 more
- Conditions
- Arthritis, Psoriatic
- Interventions
- golimumab, Placebo; golimumab
- Biological
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • La Jolla, California • Upland, California + 15 more
- Conditions
- Nausea, Vomiting
- Interventions
- ginger, placebo
- Dietary Supplement · Other
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 745 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 19
- States / cities
- Mobile, Alabama • Honolulu, Hawaii • Chicago, Illinois + 16 more
- Conditions
- GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
- Interventions
- US-ATG-F, Placebo
- Biological
- Lead sponsor
- Neovii Biotech
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 26
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 20 more
- Conditions
- Obesity, Hypertension
- Interventions
- Atkins diet (low carbohydrate diet), DASH diet (high carbohydrate diet)
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
- Interventions
- etakafusp alfa (AB248), pembrolizumab
- Biological
- Lead sponsor
- Asher Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 20
- States / cities
- Duarte, California • Los Angeles, California • San Diego, California + 15 more
- Conditions
- Arrhythmias, Cardiac, Bradycardia, Tachycardia
- Interventions
- cardiac implantable electronic devices (CIEDs)
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Gainesville, Florida • Macon, Georgia • Portland, Oregon + 5 more
- Conditions
- Metastatic Melanoma
- Interventions
- vemurafenib + HD IL-2
- Drug
- Lead sponsor
- Clinigen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 18 more
- Conditions
- Hearing Loss, Sensorineural, Hearing Loss, Conductive, Hearing Loss, Mixed Conductive-Sensorineural, Otosclerosis, Tympanic Membrane Perforation, Otitis Media With Effusion, Cholesteatoma
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 20 Years to 89 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Mountain Home, Tennessee
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Interventions
- Angel® Catheter
- Device
- Lead sponsor
- BiO2 Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Clazosentan, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more
- Conditions
- Prostate Cancer
- Interventions
- Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir
- Biological
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2030
- U.S. locations
- 72
- States / cities
- Gilbert, Arizona • Glendale, Arizona • Peoria, Arizona + 56 more